These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 37314419)

  • 1. Modelling the potential long-term survival benefit of evinacumab treatment vs. standard of care in patients with homozygous familial hypercholesterolaemia.
    Gu J; Kuznik A; Quon P; Chauhan A; Sravya TS; Raal FJ
    Eur J Prev Cardiol; 2023 Nov; 30(17):1874-1880. PubMed ID: 37314419
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Contemporary lipid-lowering management and risk of cardiovascular events in homozygous familial hypercholesterolaemia: insights from the Italian LIPIGEN Registry.
    D'Erasmo L; Bini S; Casula M; Gazzotti M; Bertolini S; Calandra S; Tarugi P; Averna M; Iannuzzo G; Fortunato G; Catapano AL; Arca M;
    Eur J Prev Cardiol; 2024 Jun; 31(8):1038-1047. PubMed ID: 38374534
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Effect of PCSK9 Inhibitors on LDL-C Target Achievement in Patients with Homozygous Familial Hypercholesterolemia: A Retrospective Cohort Analysis.
    Alshahrani A; Kholaif N; Al-Khnifsawi M; Zarif H; Mahzari M
    Adv Ther; 2024 Feb; 41(2):837-846. PubMed ID: 38169062
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evinacumab and Cardiovascular Outcome in Patients With Homozygous Familial Hypercholesterolemia.
    Béliard S; Saheb S; Litzler-Renault S; Vimont A; Valero R; Bruckert É; Farnier M; Gallo A
    Arterioscler Thromb Vasc Biol; 2024 Jun; 44(6):1447-1454. PubMed ID: 38695169
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Long-Term Efficacy and Safety of Evinacumab in Patients With Homozygous Familial Hypercholesterolemia.
    Raal FJ; Rosenson RS; Reeskamp LF; Kastelein JJP; Rubba P; Duell PB; Koseki M; Stroes E; Ali S; Banerjee P; Chan KC; Khilla N; McGinniss J; Pordy R; Zhang Y; Gaudet D
    JACC Adv; 2023 Nov; 2(9):100648. PubMed ID: 38938723
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Current treatments for the management of homozygous familial hypercholesterolaemia: a systematic review and commentary.
    Gu J; Gupta RN; Cheng HK; Xu Y; Raal FJ
    Eur J Prev Cardiol; 2024 Nov; 31(15):1833-1849. PubMed ID: 38640433
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Improved lipid-lowering treatment and reduction in cardiovascular disease burden in homozygous familial hypercholesterolemia: The SAFEHEART follow-up study.
    Alonso R; Arroyo-Olivares R; Díaz-Díaz JL; Fuentes-Jiménez F; Arrieta F; de Andrés R; Gonzalez-Bustos P; Argueso R; Martin-Ordiales M; Martinez-Faedo C; Illán F; Saenz P; Donate JM; Sanchez Muñoz-Torrero JF; Martinez-Hervas S; Mata P
    Atherosclerosis; 2024 Jun; 393():117516. PubMed ID: 38523000
    [TBL] [Abstract][Full Text] [Related]  

  • 8. LDL cholesterol target achievement in heterozygous familial hypercholesterolemia patients according to 2019 ESC/EAS lipid guidelines: Implications for newer lipid-lowering treatments.
    Rizos CV; Skoumas I; Rallidis L; Skalidis E; Tziomalos K; Garoufi A; Anagnostis P; Sfikas G; Kotsis V; Doumas M; Kolovou G; Lambadiari V; Dima I; Kiouri E; Zacharis E; Agapakis D; Attilakos A; Antza C; Vlachopoulos C; Liberopoulos EN
    Int J Cardiol; 2021 Dec; 345():119-124. PubMed ID: 34687802
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Will evinacumab become the standard treatment for homozygous familial hypercholesterolemia?
    Doggrell SA
    Expert Opin Biol Ther; 2021 Mar; 21(3):299-302. PubMed ID: 33295805
    [No Abstract]   [Full Text] [Related]  

  • 10. Evinacumab for Pediatric Patients With Homozygous Familial Hypercholesterolemia.
    Wiegman A; Greber-Platzer S; Ali S; Reijman MD; Brinton EA; Charng MJ; Srinivasan S; Baker-Smith C; Baum S; Brothers JA; Hartz J; Moriarty PM; Mendell J; Bihorel S; Banerjee P; George RT; Hirshberg B; Pordy R
    Circulation; 2024 Jan; 149(5):343-353. PubMed ID: 37860863
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Simulation of lipid-lowering therapy (LLT) intensification in very high-risk patients with atherosclerotic cardiovascular disease.
    Gu J; Sanchez RJ; Chauhan A; Fazio S; Rosenson RS
    J Clin Lipidol; 2022; 16(6):901-905. PubMed ID: 36319536
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evinacumab-dgnb (Evkeeza-REGN1500), A Novel Lipid-Lowering Therapy for Homozygous Familial Hypercholesterolemia.
    White RT; Sankey KH; Nawarskas JJ
    Cardiol Rev; 2024 Mar-Apr 01; 32(2):180-185. PubMed ID: 37071085
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Achieved LDL cholesterol levels in patients with heterozygous familial hypercholesterolemia: A model that explores the efficacy of conventional and novel lipid-lowering therapy.
    Hartgers ML; Besseling J; Stroes ES; Wittekoek J; Rutten JHW; de Graaf J; Visseren FLJ; Imholz BPM; Roeters van Lennep JE; Huijgen R; Kastelein JJP; Hovingh GK
    J Clin Lipidol; 2018; 12(4):972-980.e1. PubMed ID: 29934068
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evinacumab in homozygous familial hypercholesterolaemia: long-term safety and efficacy.
    Gaudet D; Greber-Platzer S; Reeskamp LF; Iannuzzo G; Rosenson RS; Saheb S; Stefanutti C; Stroes E; Wiegman A; Turner T; Ali S; Banerjee P; Drewery T; McGinniss J; Waldron A; George RT; Zhao XQ; Pordy R; Zhao J; Bruckert E; Raal FJ
    Eur Heart J; 2024 Jul; 45(27):2422-2434. PubMed ID: 38856678
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Advancements in the Treatment of Homozygous Familial Hypercholesterolemia.
    Bajaj A; Cuchel M
    J Atheroscler Thromb; 2022 Aug; 29(8):1125-1135. PubMed ID: 35466160
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An estimation of the consequences of reinforcing the 2016 and 2019 European Society of Cardiology/European Atherosclerosis Society guidelines on current lipid-lowering treatment in patients with type 2 diabetes in tertiary care-a SwissDiab study.
    Singeisen H; Renström F; Laimer M; Lehmann R; Bilz S; Brändle M
    Eur J Prev Cardiol; 2023 Oct; 30(14):1473-1481. PubMed ID: 37226890
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Real-World Efficacy of Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors (PCSK9i) in Heterozygous Familial Hypercholesterolemia Patients Referred for Lipoprotein Apheresis.
    Matta A; Bongard V; Bouisset F; Taraszkiewicz D; Rabès JP; Ferrières J
    Med Sci Monit; 2021 May; 27():e928784. PubMed ID: 33958572
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Usefulness of Gemcabene in Homozygous Familial Hypercholesterolemia (from COBALT-1).
    Gaudet D; Durst R; Lepor N; Bakker-Arkema R; Bisgaier C; Masson L; Golden L; Kastelein JJ; Hegele RA; Stein E
    Am J Cardiol; 2019 Dec; 124(12):1876-1880. PubMed ID: 31685212
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of a monoclonal antibody to PCSK9, REGN727/SAR236553, to reduce low-density lipoprotein cholesterol in patients with heterozygous familial hypercholesterolaemia on stable statin dose with or without ezetimibe therapy: a phase 2 randomised controlled trial.
    Stein EA; Gipe D; Bergeron J; Gaudet D; Weiss R; Dufour R; Wu R; Pordy R
    Lancet; 2012 Jul; 380(9836):29-36. PubMed ID: 22633824
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Variation in Lipid-Lowering Therapy Use in Patients With Low-Density Lipoprotein Cholesterol ≥190 mg/dL: Insights From the National Cardiovascular Data Registry-Practice Innovation and Clinical Excellence Registry.
    Virani SS; Kennedy KF; Akeroyd JM; Morris PB; Bittner VA; Masoudi FA; Stone NJ; Petersen LA; Ballantyne CM
    Circ Cardiovasc Qual Outcomes; 2018 May; 11(5):e004652. PubMed ID: 29748356
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.